Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide MMX vs. Budesonide CR for Microscopic Colitis
NCT05915104Phase 2Active, not recruiting
- Sponsor
- University of Calgary
- Start
- Mar 2024
- Primary completion
- Jul 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of EPI-EE in microscopic colitis (MC), sponsored by University of Calgary. Primary endpoint: Clinical remission at 8 weeks. Started Mar 2024; status: active, not recruiting.
02
Drugs
EPI-EE
03
Conditions
microscopic colitis (MC)
Beyond the preview
Go deeper on NCT05915104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05915104.